# DEPARTMENT OF JUSTICE

## **Drug Enforcement Administration**

### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 10, 2007, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Morphine (9300), a basic class of controlled substance listed in schedules II.

The company plans to manufacture the listed controlled substance for sale as an intermediate to generic drug customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12966 Filed 7–3–07; 8:45 am]

BILLING CODE 4410-09-P

### DEPARTMENT OF JUSTICE

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Registration

By Notice dated April 18, 2006, and published in the Federal Register on April 25, 2006, (71 FR 23948), Cody Laboratories, Inc., 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Codeine (9050) Dihydrocodeine (9120) Methadone (9250) Alfentanil (9737)	 

The company plans to manufacture in bulk, for distribution to its customers.

An objection and a request for a hearing were received by the DEA. In accordance with 21 1301.33 bulk manufacturers applying for or registered in the same basic class of narcotic or non-narcotic controlled substances may submit to the DEA any comments on or objections to the issuance of a proposed application. This regulation does not provide bulk manufacturers the right to request a hearing on the proposed application. No hearing was scheduled to be heard on this matter. DEA has reviewed the objection made against this pending application and has determined that the registration of Cody Laboratories, Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Cody Laboratories, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed.

Dated: June 26, 2007.

### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12948 Filed 7–3–07; 8:45 am]

BILLING CODE 4410-09-P

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 1, 2007, Dade Behring Inc., Regulatory Affairs, Quality Systems, 20400 Mariani Avenue, Cupertino, California 95014, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Tetrahydrocannabinols (7370)	
Benzoylecgonine (9180)	
Morphine (9300)	

The company plans to produce the listed controlled substances in bulk to be used in the manufacturer of reagents and drug calibrator/controls for DEA exempt products.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–12960 Filed 7–3–07; 8:45 am] BILLING CODE 4410-09–P

DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 28, 2007, Lin Zhi International Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Tetrahydrocannabinols (7370) 3,4– Methylenedioxymethamphetam- ine (7405). Cocaine (9041) Oxycodone (9143) Hydrocodone (9193)	

Drug	Schedule
Methadone (9250)	11
Dextropropoxyphene, bulk, (9273)	11
Morphine (9300)	II

The company plans to manufacture the listed controlled substances as bulk reagents for use in drug abuse testing.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007.

## Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–12973 Filed 7–3–07; 8:45 am] BILLING CODE 4410–09–P

## DEPARTMENT OF JUSTICE

## **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 14, 2007, Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Tetrahydrocannabinols (7370)           Methylphenidate (1724)           Codeine (9050)           Dihydrocodeine (9120)           Oxycodone (9143)           Hydromorphone (9150)           Hydrocodone (9193)           Thebaine (9333)           Oxymorphone (9652)           Noroxymorphone (9668)           Fentanyl (9801)	

The company plans to manufacture the listed controlled substances in bulk for conversion and sale to dosage form manufacturers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007.

# Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–12974 Filed 7–3–07; 8:45 am] BILLING CODE 4410–09–P

# DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 9, 2007, Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Dihydromorphine (9145)	I.
Amphetamine (1100)	
Methylphenidate (1724) Amobarbital (2125)	
Pentobarbital (2270)	
Secobarbital (2315)	ii
Glutethimide (2550)	II
Codeine (9050)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Methadone (9250)	11
Methadone intermediate (9254)	
Dextropropoxyphene, bulk (non- dosage forms) (9273).	11
Morphine (9300)	II
Oxymorphone (9652)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 4, 2007.

Dated: June 26, 2007.

#### Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–12975 Filed 7–3–07; 8:45 am] BILLING CODE 4410–09–P

### DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

## Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 29, 2007, Sigma Aldrich Research Biochemicals, Inc., 1–3 Strathmore Road, Natick, Massachusetts 01760, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Cathinone (1235) Methcathinone (1237) Aminorex (1585) Alpha-ethyltryptamine (7249) Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) 4-Bromo-2,5- dimethoxyamphetamine (7391). 4-Bromo-2,5- dimethoxyphenethylamine	
<ul> <li>(7392).</li> <li>2,5-Dimethoxyamphetamine (7396).</li> <li>3,4-Methylenedioxyamphetamine (7400).</li> <li>N-Hydroxy-3,4- methylenedioxyamphetamine (7402).</li> </ul>	1